Curi RMB Capital LLC Has $20.46 Million Holdings in Becton, Dickinson and Company (NYSE:BDX)

Curi RMB Capital LLC boosted its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 18.1% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 84,873 shares of the medical instruments supplier's stock after purchasing an additional 13,030 shares during the period. Curi RMB Capital LLC's holdings in Becton, Dickinson and Company were worth $20,463,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Empowered Funds LLC boosted its holdings in shares of Becton, Dickinson and Company by 40.2% during the 1st quarter. Empowered Funds LLC now owns 4,439 shares of the medical instruments supplier's stock worth $1,098,000 after buying an additional 1,273 shares during the period. Avantax Advisory Services Inc. increased its position in Becton, Dickinson and Company by 5.0% during the 1st quarter. Avantax Advisory Services Inc. now owns 6,354 shares of the medical instruments supplier's stock worth $1,572,000 after buying an additional 301 shares during the period. Edmond DE Rothschild Holding S.A. acquired a new stake in shares of Becton, Dickinson and Company during the first quarter worth $148,000. Kingsview Wealth Management LLC boosted its position in shares of Becton, Dickinson and Company by 7.4% in the first quarter. Kingsview Wealth Management LLC now owns 4,306 shares of the medical instruments supplier's stock valued at $1,065,000 after acquiring an additional 296 shares during the period. Finally, HBK Sorce Advisory LLC grew its stake in shares of Becton, Dickinson and Company by 5.7% in the first quarter. HBK Sorce Advisory LLC now owns 3,167 shares of the medical instruments supplier's stock valued at $784,000 after acquiring an additional 172 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on BDX shares. Stifel Nicolaus boosted their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a "buy" rating in a report on Friday, July 26th. Citigroup upgraded Becton, Dickinson and Company from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. Evercore ISI upped their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an "outperform" rating in a research report on Tuesday, October 1st. Raymond James dropped their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an "outperform" rating for the company in a research note on Friday, August 2nd. Finally, StockNews.com upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Thursday, August 8th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $283.00.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock traded down $4.05 during midday trading on Thursday, reaching $227.17. The company's stock had a trading volume of 2,819,832 shares, compared to its average volume of 1,407,861. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69. The stock has a market cap of $65.66 billion, a PE ratio of 38.93, a price-to-earnings-growth ratio of 1.72 and a beta of 0.43. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $249.89. The business has a 50-day moving average price of $236.56 and a 200-day moving average price of $235.10.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The business had revenue of $5.44 billion during the quarter, compared to analysts' expectations of $5.38 billion. During the same period in the prior year, the company earned $3.42 EPS. The firm's quarterly revenue was up 6.9% compared to the same quarter last year. On average, sell-side analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th will be issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.83%. The ex-dividend date of this dividend is Monday, December 9th. This is a positive change from Becton, Dickinson and Company's previous quarterly dividend of $0.95. Becton, Dickinson and Company's payout ratio is 63.97%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.